Trials that use: Exact / Clopper-Pearson binomial
New to this method? Read the tutorial →
1,265 results
- Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy:…
- Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…
- Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pemetrexed Plus Gemcitabine in Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Plus Gemcitabine in Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00491075).
- Penicillin De-labeling in the Pediatric Primary Care Setting: Complete Statistical AnalysisIndependent statistical analysis of Penicillin De-labeling in the Pediatric Primary Care Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05010304).
- Pento & tBUIndependent statistical analysis of Phase II Trial of Pentostatin and Targeted Busulfan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00496340).
- PEPIIndependent statistical analysis of Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00578864).
- PERFECTIONIndependent statistical analysis of Evaluation of FUSION™ Vascular Graft for Above Knee Targets: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01601496).
- Peripheral Nerve Blocks for Above-the-knee Amputations: Complete Statistical AnalysisIndependent statistical analysis of Peripheral Nerve Blocks for Above-the-knee Amputations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03404180).
- PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01205646).
- PET/MR USIndependent statistical analysis of Comparison of 18F FDG PET/CT TO PET MRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01986985).
- PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03685591).
- Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00280735).
- Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo: Complete Statistical AnalysisIndependent statistical analysis of Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo: primary endpoint results, effect estimate with confidence interval, sample-size…
- Pharmacokinetics and Safety of SAR441236: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics and Safety of SAR441236: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03705169).
- Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD): primary endpoint results, effect estimate with confidence…
- Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04711005).
- Phase 1 Study of PBTZ169: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Study of PBTZ169: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03036163).
- Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00711997).
- Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase 2 Herniorrhaphy Study for Opioid Elimination: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Herniorrhaphy Study for Opioid Elimination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03695367).
- Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00530816).
- Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: primary endpoint results, effect estimate…
- Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant: Complete Statistical AnalysisIndependent statistical analysis of Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity: Complete Statistical AnalysisIndependent statistical analysis of Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase I Combination Ixabepilone + Cisplatin: Complete Statistical AnalysisIndependent statistical analysis of Phase I Combination Ixabepilone + Cisplatin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00832117).
- Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP): Complete Statistical AnalysisIndependent statistical analysis of Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00356993).
- Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02047500).
- Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: primary endpoint results, effect estimate with confidence…
- Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Dasatinib Study in Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Dasatinib Study in Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00546104).
- Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Neoadjuvant in Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Neoadjuvant in Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00756470).